AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

- Claim 1. (Currently Amended) Composition intended for the implementation of a cytotoxic treatment in mammals, comprising:
- (i) a nucleic acid sequence encoding all or part of an MIP chemokine or a natural variant of MIP1 α or MIP1 β ,
- (ii) at least one nucleic acid sequence encoding IL-2,
 said nucleic acid sequences being placed under the control of the
 elements required for their expression in a host cell of said mammal;

wherein the compound is directly administered via a vector or a mixture of vectors expressing both IL-2 and a MIP chemokine;

and wherein the IL-2 and MIP chemokine work together synergistically.

Claims 2-6. (Canceled)

Claim 7. (Currently Amended) The composition according to Claim 1, comprising in (ii) at least two nucleic acid sequences encoding interleukin-2 (IL-2) and all or part of interferon gamma (IFN-y).

Claim 8-10. (Canceled)

- Claim 11. (Previously Presented) Composition according to Claim 1, wherein said nucleic acid sequences (i) and (ii) are inserted into a recombinant vector of plasmid or viral origin.
- Claim 12. (Previously Presented) Composition according to Claim 11, wherein said nucleic acid sequences (i) and (ii) are inserted into the same recombinant vector.
- Claim 13. (Previously Presented) Composition according to Claim 11, wherein said nucleic acid sequences (i) and (ii) are inserted into distinct recombinant vectors.
 - Claim 14. (Previously Presented) Vector comprising:
- (i) a nucleic acid sequence encoding MIP1 α , MIP1 β chemokine or a natural variant of MIP1 α or MIP1 β , and
- (ii) at least one nucleic acid sequence encoding IL-2, said nucleic acid sequences being placed under the control of the elements required for their expression in a host cell.

Claim 15. (Previously Presented) Vector according to Claim 14, wherein it is a viral vector.

Claims 16-18. (Canceled)

Claim 19. (Currently Amended) Formulation intended for the implementation of a cytotoxic treatment in mammals, comprising a the composition according to Claim 13, or Claim 1, and a support which is pharmaceutically acceptable.

Claim 20. (Previously Presented) Formulation according to Claim 19, comprising capable of being transformed into a cytotoxic molecule by a polypeptide having at least cytotoxic activity.

Claims 21-23. (Canceled)

Claim 24. (Previously Presented) A method for treating a proliferative disease in a patient in need, said method comprising administering an effective amount of the composition of Claim 1 by direct administration into an accessible tumor or at its periphery.

- Claim 25. (Previously Presented) The composition according to claim 13, wherein said recombinant vectors are adenoviral vectors defective for the replication.
- Claim 26. (Previously Presented) The vector of claim 15, wherein said viral vector is an adenoviral vector deriving from an adenovirus.
- Claim 27. (Previously Presented) The vector of claim 26, wherein said adenoviral vector is defective for replication.
- Claim 28. (Previously Presented) The vector of claim 27, wherein said adenoviral vector defective for replication is deleted of the E1 region.
- Claim 29. (Previously Presented) The vector of claim 27, wherein said adenoviral vector defective for replication is deleted of the majority of the E1 and of the E4 regions.
- Claim 30. (Previously Presented) The vector of claim 28 or 29, further lacking all or part of the E3 region.
- Claim 31. (Previously Presented) The vector of claim 15, wherein said viral vector is a poxviral vector deriving from a poxvirus.

Claim 32. (Currently Amended) the <u>The</u> vector of claim 31, wherein said poxvirus is selected from the group consisting of vaccinia virus, MVA and canarypox.